Pan-selectin antagonism improves psoriasis manifestation in mice and man
dc.contributor.author | Wolff, Gerhard | en_US |
dc.contributor.author | Wolk, Kerstin | en_US |
dc.contributor.author | Dam, Tomas Norman | en_US |
dc.contributor.author | Philipp, Sandra | en_US |
dc.contributor.author | Sabat, Robert | en_US |
dc.contributor.author | Ludwig, Nina | en_US |
dc.contributor.author | Aydt, Ewald | en_US |
dc.contributor.author | Zahlten, Rainer | en_US |
dc.contributor.author | Sterry, Wolfram | en_US |
dc.contributor.author | Kang, Sewon | en_US |
dc.contributor.author | Schroeter-Maas, Sabine | en_US |
dc.contributor.author | Friedrich, Markus | en_US |
dc.contributor.author | Bock, Daniel | en_US |
dc.date.accessioned | 2006-09-11T18:45:54Z | |
dc.date.available | 2006-09-11T18:45:54Z | |
dc.date.issued | 2006-02 | en_US |
dc.identifier.citation | Friedrich, Markus; Bock, Daniel; Philipp, Sandra; Ludwig, Nina; Sabat, Robert; Wolk, Kerstin; Schroeter-Maas, Sabine; Aydt, Ewald; Kang, Sewon; Dam, Tomas Norman; Zahlten, Rainer; Sterry, Wolfram; Wolff, Gerhard; (2006). "Pan-selectin antagonism improves psoriasis manifestation in mice and man." Archives of Dermatological Research 297(8): 345-351. <http://hdl.handle.net/2027.42/47253> | en_US |
dc.identifier.issn | 1432-069X | en_US |
dc.identifier.issn | 0340-3696 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/47253 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16362415&dopt=citation | en_US |
dc.description.abstract | The selectin family of vascular cell adhesion molecules is comprised of structurally related carbohydrate binding proteins, which mediate the initial rolling of leukocytes on the activated vascular endothelium. Because this process is one of the crucial events in initiating and maintaining inflammation, selectins are proposed to be an attractive target for the development of new antiinflammatory therapeutics. Here, we demonstrate that the synthetic pan-selectin antagonist bimosiamose is effective in pre-clinical models of psoriasis as well as in psoriatic patients. In vitro bimosiamose proved to be inhibitory to E- or P-selectin dependent lymphocyte adhesion under flow conditions. Using xenogeneic transplantation models, bimosiamose reduced disease severity as well as development of psoriatic plaques in symptomless psoriatic skin. The administration of bimosiamose in patients suffering from psoriasis resulted in a reduction of epidermal thickness and lymphocyte infiltration. The clinical improvement was statistically significant ( P =0.02) as analyzed by comparison of psoriasis area and severity index before and after treatment. Assessment of safety parameters showed no abnormal findings. These data suggest that pan-selectin antagonism may be a promising strategy for the treatment of psoriasis and other inflammatory diseases. | en_US |
dc.format.extent | 249913 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Springer-Verlag | en_US |
dc.subject.other | Selectins | en_US |
dc.subject.other | Psoriasis | en_US |
dc.subject.other | Inflammation | en_US |
dc.subject.other | Antagonists | en_US |
dc.title | Pan-selectin antagonism improves psoriasis manifestation in mice and man | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Dermatology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Dermatology, The University of Michigan, 1301 Catherine Road, Box 0602, Ann Arbor, MI, 48109, USA, | en_US |
dc.contributor.affiliationum | Department of Dermatology, The University of Michigan, 1301 Catherine Road, Box 0602, Ann Arbor, MI, 48109, USA, | en_US |
dc.contributor.affiliationother | Revotar Biopharmaceuticals AG, Neuendorfstr. 24a, 16761, Hennigsdorf, Germany, | en_US |
dc.contributor.affiliationother | Department of Dermatology and Allergy, University Hospital Charité, Schumannstr. 20/21, 10117, Berlin, Germany, ; Interdisciplinary group of Molecular Immunopathology, Dermatology/Med.Immunology, University Hospital Charité, Schumannstr. 20/21, 10117, Berlin, Germany, | en_US |
dc.contributor.affiliationother | Revotar Biopharmaceuticals AG, Neuendorfstr. 24a, 16761, Hennigsdorf, Germany, | en_US |
dc.contributor.affiliationother | Department of Dermatology and Allergy, University Hospital Charité, Schumannstr. 20/21, 10117, Berlin, Germany, ; Interdisciplinary group of Molecular Immunopathology, Dermatology/Med.Immunology, University Hospital Charité, Schumannstr. 20/21, 10117, Berlin, Germany, | en_US |
dc.contributor.affiliationother | Revotar Biopharmaceuticals AG, Neuendorfstr. 24a, 16761, Hennigsdorf, Germany, | en_US |
dc.contributor.affiliationother | Revotar Biopharmaceuticals AG, Neuendorfstr. 24a, 16761, Hennigsdorf, Germany, | en_US |
dc.contributor.affiliationother | Interdisciplinary group of Molecular Immunopathology, Dermatology/Med.Immunology, University Hospital Charité, Schumannstr. 20/21, 10117, Berlin, Germany, | en_US |
dc.contributor.affiliationother | Revotar Biopharmaceuticals AG, Neuendorfstr. 24a, 16761, Hennigsdorf, Germany, | en_US |
dc.contributor.affiliationother | Department of Dermatology and Allergy, University Hospital Charité, Schumannstr. 20/21, 10117, Berlin, Germany, | en_US |
dc.contributor.affiliationother | Department of Dermatology and Allergy, University Hospital Charité, Schumannstr. 20/21, 10117, Berlin, Germany, ; Interdisciplinary group of Molecular Immunopathology, Dermatology/Med.Immunology, University Hospital Charité, Schumannstr. 20/21, 10117, Berlin, Germany, | en_US |
dc.contributor.affiliationother | Interdisciplinary group of Molecular Immunopathology, Dermatology/Med.Immunology, University Hospital Charité, Schumannstr. 20/21, 10117, Berlin, Germany, | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 16362415 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/47253/1/403_2005_Article_626.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/s00403-005-0626-0 | en_US |
dc.identifier.source | Archives of Dermatological Research | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.